NurExone Biologic Inc. (TSXV:NRX)

NurExone Biologic Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	0.98	0.7	0.54	2.46	2.21	0.01
Cash & Short-Term Investments	0.98	0.7	0.54	2.46	2.21	0.01
Cash Growth	-61.04%	29.39%	-78.03%	11.25%	32528.30%	293.24%
Other Receivables	0.12	0.29	0.21	0.18	0.6	-
Total Trade Receivables	0.12	0.29	0.21	0.18	0.6	-
Inventory	0.62	-	-	-	-	-
Other Current Assets	0.04	0.64	1.23	0.05	0.02	0.01
Total Current Assets	1.15	1.63	1.98	2.69	2.84	0.01
Net Property, Plant & Equipment	0.88	0.81	0.19	0.1	-	-
Total Assets	2.65	2.44	2.17	2.79	2.84	0.01
Accounts Payable	0.5	0.23	0.32	0.3	0.26	0.06
Accrued Expenses	0.37	0.17	0.3	0.31	0.09	-
Short-Term Debt	-	-	-	-	1.04	-
Unearned Revenue	-	-	0.1	-	-	-
Other Current Liabilities	-	-	1.2	-	0.24	0.02
Total Current Liabilities	0.86	0.4	1.91	0.6	1.63	0.08
Long-Term Leases	0.08	0.03	0	0.02	-	-
Other Long-Term Liabilities	0.25	0.25	0.07	0.08	0.03	-
Total Long-Term Liabilities	0.33	0.28	0.07	0.1	0.03	-
Total Liabilities	1.19	0.68	1.98	0.7	1.66	0.08
Common Stock	-	-	-	-	-	0.95
Additional Paid-in Capital	25.59	21.06	14.29	12.59	3.43	0.01
Accumulated Other Comprehensive Income	-0.05	-0.2	-0.05	-0.07	-0.01	-
Retained Earnings	-24.09	-19.1	-14.06	-10.42	-2.25	-1.02
Shareholders' Equity	1.46	1.76	0.19	2.1	1.18	-0.07
Total Liabilities & Equity	2.65	2.44	2.17	2.79	2.84	0.01
Total Debt	0.08	0.03	0	0.02	1.04	0
Net Cash (Debt)	0.9	0.67	0.54	2.44	1.17	0.01
Net Cash Growth	35.13%	24.12%	-77.94%	108.63%	17157.34%	293.24%
Net Cash Per Share	0.01	0.01	0.01	0.07	0.07	0.00
Book Value	1.46	1.76	0.19	2.1	1.18	-0.07
Book Value Per Share	0.02	0.03	0.00	0.06	0.07	-0.03
Tangible Book Value	1.46	1.76	0.19	2.1	1.18	-0.07
Tangible Book Value Per Share	0.02	0.03	0.00	0.06	0.07	-0.03

Updated Sep 30, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.